Share price Teva Pharmaceutical Industries Limited (New York Stock Exchange: Tifa; level: tifa) It rose 8.1% last week on Wall Street, giving a market cap of $23.5 billion. Since the stock’s lowest point in 2025 in April, the stock price has risen more than 60%.
The Israeli pharmaceutical company, run by CEO Richard Francis, will publish its third-quarter financial results on Wednesday. According to Yahoo Finance, analysts expect revenue to be similar to the corresponding quarter in 2024 – $4.33 billion, and non-GAAP EPS of $0.67, down $0.02 from the corresponding quarter.
Related articles
Teva raises earnings guidance again
Teva is recycling debt after rating upgrade
According to the Wall Street Journal, of the 10 analysts covering Teva stock, nine are positive and one is negative, and the average price target is $25.57 — a 24.9% premium to the current stock price. Last week, Jefferies analyst Dennis Deng published a review ahead of the Teva report and addressed the issue of IRA legislation designed to lower US drug prices in, among other things, the pharmaceutical sector. Ding notes that investors will focus on what Teva’s management has said about the impact on Austedo (a brand-name drug for movement disorders) and estimates that the company’s forecast of $2.5 billion in sales from Austedo in 2027 will likely not change. This is despite the fact that the price of the drug is expected to fall.
Ding gives a “buy” recommendation on Teva stock with a target price of $24, a premium of 17.2%. Meanwhile, Teva announced it had won an Excellence Award at the Economist Group’s EuroFinance Treasury Conference, for improving the company’s cash and working capital management.
Published by Globes, Israel Business News – en.globes.co.il – on November 3, 2025.
© Copyright Globes Publisher Itonut (1983) Ltd., 2025.
The post Teva jumps ahead of Q3 results first appeared on Investorempires.com.
